Bioxytran Q2 net loss turns to $619,929; H1 net loss widens to $2.69 million
BIXT•Cash position weakens
Cash fell to $177,384 at June 30, 2026 from $509,914 at year-end; management said it expects cash to run out by September 2026.
Quarterly loss and per-share results
Bioxytran posted a net loss attributable to shareholders of $619,929, swinging from a net profit of $35,439 a year earlier.
Loss per share was $0.01, turning from break-even EPS of $0.00 in the prior-year quarter.
Costs rise in research, development and administration
Research and development expense climbed to $255,479 from $102,500, driven by higher regulatory costs of $210,719.
General and administrative expense rose to $399,121 from $121,577, reflecting payroll of $262,567 after no payroll last year.
